![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Loxo Oncology Secures Breakthrough Designation
Loxo Oncology Secures Breakthrough Designation
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/KeytoSuccess.gif?t=1474505946&width=430)
July 20, 2016
Loxo Oncology has scooped up a breakthrough therapy designation for its tropomyosin receptor kinase inhibitor candidate LOXO-101, the Stamford, Conn.-based company announced.
The drug candidate is designed to treat unresectable or metastatic solid tumors that have NTRK-fusion proteins in adult and pediatric patients with disease progression after treatment or those who don’t have other appropriate options.
Upcoming Events
-
21Oct